| General Information | |
|---|---|
| ZINC ID | ZINC000028962213 |
| Molecular Weight (Da) | 374 |
| SMILES | O=C(NC1CCCCCC1)c1cn(Cc2ccccc2)c2ccccc2c1=O |
| Molecular Formula | C24N2O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 109.009 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 28 |
| LogP | 5.223 |
| Activity (Ki) in nM | 16.9824 |
| Polar Surface Area (PSA) | 51.1 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 1.128 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.33 |
| Ilogp | 3.83 |
| Xlogp3 | 5.03 |
| Wlogp | 4.5 |
| Mlogp | 3.2 |
| Silicos-it log p | 4.47 |
| Consensus log p | 4.21 |
| Esol log s | -5.42 |
| Esol solubility (mg/ml) | 0.00141 |
| Esol solubility (mol/l) | 0.00000377 |
| Esol class | Moderately |
| Ali log s | -5.84 |
| Ali solubility (mg/ml) | 0.000536 |
| Ali solubility (mol/l) | 0.00000143 |
| Ali class | Moderately |
| Silicos-it logsw | -7.36 |
| Silicos-it solubility (mg/ml) | 0.0000163 |
| Silicos-it solubility (mol/l) | 4.35E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.01 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 2.75 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.95 |
| Logd | 3.748 |
| Logp | 4.681 |
| F (20%) | 0.958 |
| F (30%) | 0.994 |
| Mdck | - |
| Ppb | 96.87% |
| Vdss | 2.604 |
| Fu | 1.32% |
| Cyp1a2-inh | 0.535 |
| Cyp1a2-sub | 0.133 |
| Cyp2c19-inh | 0.874 |
| Cyp2c19-sub | 0.071 |
| Cl | 2.879 |
| T12 | 0.052 |
| H-ht | 0.618 |
| Dili | 0.464 |
| Roa | 0.283 |
| Fdamdd | 0.743 |
| Skinsen | 0.71 |
| Ec | 0.003 |
| Ei | 0.027 |
| Respiratory | 0.137 |
| Bcf | 0.859 |
| Igc50 | 4.748 |
| Lc50 | 5.152 |
| Lc50dm | 5.496 |
| Nr-ar | 0.286 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.822 |
| Nr-aromatase | 0.873 |
| Nr-er | 0.32 |
| Nr-er-lbd | 0.005 |
| Nr-ppar-gamma | 0.766 |
| Sr-are | 0.438 |
| Sr-atad5 | 0.03 |
| Sr-hse | 0.657 |
| Sr-mmp | 0.732 |
| Sr-p53 | 0.455 |
| Vol | 405.28 |
| Dense | 0.923 |
| Flex | 0.192 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.684 |
| Synth | 1.964 |
| Fsp3 | 0.333 |
| Mce-18 | 48.75 |
| Natural product-likeness | -1.055 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |